Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-10T13:16:28.875Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-term efficacy of standardised specific subcutaneous immunotherapy in children with persistent allergic rhinitis due to multiple allergens including house dust mites

Published online by Cambridge University Press:  28 January 2018

Y Song ,
J Long ,
T Wang ,
J Xie ,
M Wang  and
G Tan
Y Song
Affiliation:
Department of Otolaryngology – Head Neck Surgery, Third Xiangya Hospital of Central South University, Changsha, Hunan, China
J Long
Affiliation:
Department of Otolaryngology – Head Neck Surgery, Third Xiangya Hospital of Central South University, Changsha, Hunan, China
T Wang
Affiliation:
Department of Otolaryngology – Head Neck Surgery, Third Xiangya Hospital of Central South University, Changsha, Hunan, China
J Xie
Affiliation:
Department of Otolaryngology – Head Neck Surgery, Hunan Children's Hospital, Changsha, China
M Wang
Affiliation:
Department of Otolaryngology – Head Neck Surgery, Hunan Children's Hospital, Changsha, China
G Tan*
Affiliation:
Department of Otolaryngology – Head Neck Surgery, Third Xiangya Hospital of Central South University, Changsha, Hunan, China
*
Address for correspondence: Professor Guolin Tan, Department of Otolaryngology – Head Neck Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China Fax: +86 731 886 18536 E-mail: guolintanent@163.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives:

To observe the five-year efficacy of standardised specific subcutaneous immunotherapy for house dust mite allergy in monosensitised and polysensitised children with persistent allergic rhinitis.

Methods:

From January 2007 to August 2009, 236 children with persistent allergic rhinitis were divided into 2 groups: 1 group received standardised specific subcutaneous immunotherapy using house dust mite extract; the other received pharmacotherapy with intranasal corticosteroids and oral antihistamines. A total of 193 patients (106 in the immunotherapy group and 87 in the pharmacotherapy group) completed treatment. Scores for symptoms, total medication and quality of life were evaluated.

Results:

The subcutaneous immunotherapy group demonstrated a significant reduction in visual analogue scale scores, Rhinoconjunctivitis Quality of Life Questionnaire scores and total medication scores (p < 0.05) compared with the pharmacotherapy group. No significant differences in the visual analogue scale and Rhinoconjunctivitis Quality of Life Questionnaire scores were found between the polysensitised and monosensitised subgroups (p > 0.05). No serious adverse events occurred.

Conclusion:

Standardised subcutaneous immunotherapy has long-term efficacy for children with persistent allergic rhinitis. Single-allergen subcutaneous immunotherapy was appropriate for allergic rhinitis caused by multiple allergens, including house dust mites, in the paediatric population.

Keywords

ImmunotherapyHouse Dust MitesChildrenAllergic Rhinitis
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 132 , Issue 3 , March 2018 , pp. 230 - 235
Copyright
Copyright © JLO (1984) Limited 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Meltzer, EO, Bukstein, DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol 2011;106:S12–16 CrossRefGoogle ScholarPubMed
2 Bousquet, J, Khaltaev, N, Cruz, AA, Denburg, J, Fokkens, WJ, Togias, A et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63:8–160 Google Scholar
3 Song, Y, Wang, M, Xie, J, Li, W, Zhang, X, Wang, T et al. Prevalence of allergic rhinitis among elementary and middle school students in Changsha city and its impact on quality of life. J Laryngol Otol 2015;129:1108–14Google Scholar
4 Stewart, MG. Identification and management of undiagnosed and undertreated allergic rhinitis in adults and children. Clin Exp Allergy 2008;38:751–60Google Scholar
5 Jacobsen, L, Niggemann, B, Dreborg, S, Ferdousi, HA, Halken, S, Høst, A et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007;62:943–8Google Scholar
6 Dong, X, Huang, N, Li, W, Hu, L, Wang, X, Wang, Y et al. Systemic reactions to dust mite subcutaneous immunotherapy: a 3-year follow-up study. Allergy Asthma Immunol Res 2016;8:421–7Google Scholar
7 Tabar, AI, Arroabarren, E, Echechipía, S, García, BE, Martin, S, Alvarez-Puebla, MJ. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol 2011;127:57–63 CrossRefGoogle ScholarPubMed
8 Canonica, GW, Cox, L, Pawankar, R, Baena-Cagnani, CE, Blaiss, M, Bonini, S et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014;7:6 CrossRefGoogle ScholarPubMed
9 Noon, L. Prophylactic inoculation against hay fever. Historical document. Ann Allergy 1960;18:287–91Google Scholar
10 Durham, SR, Walker, SM, Varga, EM, Jacobson, MR, O'Brien, F, Noble, W et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468–75Google Scholar
11 Möller, C, Dreborg, S, Ferdousi, HA, Halken, S, Høst, A, Jacobsen, L et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251–6CrossRefGoogle ScholarPubMed
12 Calderón, MA, Cox, L, Casale, TB, Moingeon, P, Demoly, P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol 2012;129:929–34Google Scholar
13 Bahceciler, NN, Galip, N, Cobanoglu, N. Multiallergen-specific immunotherapy in polysensitized patients: where are we? Immunotherapy 2013;5:183–90Google Scholar
14 Soyyigit, S, Guloglu, D, Ikinciogullari, A, Secil, D, Oztuna, D, Mungan, D et al. Immunologic alterations and efficacy of subcutaneous immunotherapy with Dermatophagoides pteronyssinus in monosensitized and polysensitized patients. Ann Allergy Asthma Immunol 2016;116:244–51Google Scholar
15 Kim, SH, Shin, SY, Lee, KH, Kim, SW, Cho, JS. Long-term effects of specific allergen immunotherapy against house dust mites in polysensitized patients with allergic rhinitis. Allergy Asthma Immunol Res 2014;6:535–40Google Scholar
16 Bernstein, DI, Epstein, T, Murphy-Berendts, K, Liss, GM. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study. Ann Allergy Asthma Immunol 2010;104:530–5Google Scholar